JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Whitepaper
Preclinical screening platforms for antibody-drug conjugate therapeutics
Antibody-Drug Conjugates (ADCs) are at the cutting edge of oncology research, offering a groundbreaking approach to targeting cancer cells while minimizing damage to healthy tissue.
This white paper explores the latest advancements in ADC development, including innovations in drug delivery, strategies for overcoming treatment resistance, and preclinical screening platforms to optimize efficacy.
If you're looking for insights into the next breakthrough in cancer medicine, this is essential reading.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Preclinical screening platforms for antibody-drug conjugate therapeutics